Airway Innovations, Inc.

03/17/2026

We’re excited to announce another major step forward for Airway Innovations — our exclusive distribution partnership with Medical Specialties.

This collaboration expands access to the AERIS Airway™ across the Southern U.S., empowering hospitals and ambulatory surgery centers to deliver simpler, safer I.V. sedation, total I.V. anesthesia, and post-extubation care.

Together, we’re advancing airway management by helping anesthesia providers enhance patient safety, streamline workflows, and exceed current American Society of Anesthesiologists standards with modern, evidence-based innovation.

Learn more about this partnership and the future of airway management by clicking the link below.

03/17/2026

The American Society of Anesthesiologists recommends ETCO₂ monitoring during deep to moderate sedation to help reduce hypoxic events. Unfortunately, current ETCO₂ monitoring methods during sedation are unreliable. The AERIS Airway™ provides better, high-efficiency oxygen delivery with more reliable real-time CO₂ monitoring to help clinicians detect respiratory depression and enhance patient safety. Learn more about this breakthrough in sedation airway management at:https://hubs.ly/Q045mDQ40

03/04/2026

We had a great time connecting with Missouri anesthesia providers at the Missouri Society of Anesthesiologists Annual Meeting in Kansas City, MO, on February 27–28.

Pictured are our SVP of Sales & Marketing, Chris Klecher, and Jennifer Kelley from MED Alliance Group, Inc.—our outstanding distribution partner for the AERIS Airway. MED Alliance is helping us bring the AERIS Airway to more hospitals and surgery centers, giving clinicians a new option for enhanced oxygen delivery and reliable CO₂ monitoring during total IV sedation.

Attendees were excited to learn more about our AERIS device, and samples were provided to evaluate at their institutions. To request your own samples or more information, visit: https://airwayinnovations.com/contact

02/26/2026

Reimagine the Guedel OPA . . .

What if your oropharyngeal airway didn’t just stent the airway, but delivered high FiO₂ to and sampled ETCO₂ from where it matters most—the supraglottic region?

Watch how the AERIS Airway turns a basic OPA into a true patient safety device in this short video.

02/26/2026

Reimagine the NPA . . .

What if your nasopharyngeal airway didn’t just stent the airway, but delivered high FiO₂ to and sampled ETCO₂ from where it matters most—the supraglottic region?

Watch how the AERIS Airway turns a basic NPA into a true patient safety device in this short video.

02/22/2026

Hypoxemia risk during I.V. sedation is unacceptably high—but it doesn’t have to stay that way . . .

The AERIS Airway™ delivers ~2.5–3.5x higher supraglottic FiO₂ than divided nasal cannulas or oxygen face masks, while simultaneously providing a precise ETCO₂ waveform. This combination of superior oxygenation and reliable capnography gives anesthesia providers a powerful new way to protect patients during moderate to deep sedation—and to intervene earlier when ventilation begins to deteriorate.

HUGE THANKS to our partners at MED Alliance Group, Inc. for highlighting how the AERIS Airway is redefining safety standards in I.V. sedation by sharing our clinical study!

Providing effective supplemental oxygen during procedural sedation is crucial to prevent hypoxia and its potential consequences. A recent White Paper that compared supraglottic FiO2 provided by oxygen masks, nasal cannulas and the AERIS Airway™, found that the AERIS provided better oxygenation, more reliable CO2 monitoring and safer sedation.

Achieving 80-90% FiO2 at oxygen flow rates of 2-4 L/min, the AERIS modernizes the practice of deep sedation, limits the risk of hypoxia and decreases the amount of oxygen needed to maintain oxygenation. Review the White Paper and learn more about this innovative breakthrough in safer sedation @ https://hubs.ly/Q03_s_M60

02/22/2026

Airway Innovations is thrilled to share that, as of January, we have entered into a strategic partnership with MED Alliance Group, Inc. to bring the AERIS Airway™ to more anesthesiologists and CRNAs across 23 states in the Midwest and much of the East Coast.

Through this collaboration, more anesthesia teams will have access to a smarter, simpler airway solution—one that enhances patient safety, streamlines perioperative workflows, and supports better outcomes at a lower cost for their hospitals and health systems.

Simple. Safer. Sedation.



https://airwayinnovations.com/news-details/airway-innovations-news-article

02/22/2026

Airway Innovations is excited to announce a strategic partnership with MetroMed, established at the start of the year, to expand access to the AERIS Airway™ across hospitals and medical facilities throughout New England.

Through this collaboration, AERIS Airway™ will be available to more anesthesiologists and CRNAs, supporting safer airway management, streamlining intraoperative workflows, and helping anesthesia teams deliver high‑quality care more efficiently.

Click below to learn how this partnership will help your anesthesia group enhance patient safety, reduce complexity in difficult airway scenarios, and support better outcomes at lower cost.

Simple. Safer. Sedation.



https://airwayinnovations.com/news-details/airway-innovations-enters-exclusive-distribution-agreement-with-metromed-to-accelerate-market-adoption-of-aeris-airway-device